Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jounce Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired
BioCentury | Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Mar 27, 2024
Management Tracks
Furuta to become CFO at Takeda
Plus: IDRx names Kerstein CMO and updates from Transgene, Noetik, Egle and MannKind
BioCentury | Jan 24, 2024
Management Tracks
Markison to succeed Heino as Lantheus CEO
Plus: Lisa Olson becomes CEO of Enthera, and updates from Bayer, Neumora, PDS and more
BioCentury | Jul 28, 2023
Deals
Biotech reverse mergers growing amid improving market conditions
Are 2023’s reverse mergers another sign of an improving biotech environment?
BioCentury | Jul 11, 2023
Management Tracks
Billy Cho joins CBC as senior managing director
Plus: Birchenough becomes chairman of global healthcare at Barclays, and updates from EyePoint, Replicate, MBX, Voyager and more
BioCentury | Mar 28, 2023
Product Development
March 27 Quick Takes: Big gain for Novartis on Kisqali readout
Plus: SR One closes $600M second fund and updates from Vertex, CRISPR; Merck KGaA, Pfizer and more
BioCentury | Mar 16, 2023
Deals
March 15 Quick Takes: Rival bid could upend Redx-Jounce deal
Plus: Dermavant’s Vtama meets Phase III endpoints, and updates from CMS, Aitia, Bellicum and more
BioCentury | Feb 23, 2023
Deals
Redx adds U.S. office while Jounce shareholders eye CVR’s upside in merger
Combined company will prioritize U.K. company’s ROCK2 program as deal adds to Redx’s balance sheet
BioCentury | Aug 30, 2022
Product Development
Aug. 30 Quick Takes: Lumakras meets in lung cancer Phase III
Plus vopratelimab miss weighs on Jounce and updates from MedGenome, Sangamo and more
BioCentury | Jun 15, 2022
Data Byte
Third Rock’s penchant for platforms, product engines
The firm has backed 11 companies since the start of 2021; none are single-asset plays
Items per page:
1 - 10 of 77